Aguilar-Cordova Estuardo
Known title: DirectorCIK: 0001873919
Associated companies
Transaction History
| CADL | ▼ Sell | Other | 10,582 | $127K | 2/21/2025 | View on chart |
| CADL | ▼ Sell | Other | 10,583 | $127K | 2/21/2025 | View on chart |
| CADL | ▼ Sell | Other | 31,335 | $270K | 2/10/2025 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $443K | 12/27/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $443K | 12/27/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $451K | 12/26/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $451K | 12/26/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $441K | 12/24/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $441K | 12/24/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $426K | 12/23/2024 | View on chart |
| CADL | ▼ Sell | Other | 50,000 | $426K | 12/23/2024 | View on chart |
| CADL | ▼ Sell | Other | 100,000 | $900K | 12/20/2024 | View on chart |
| CADL | ▼ Sell | Other | 100,000 | $900K | 12/20/2024 | View on chart |
| CADL | ▼ Sell | Other | 200,000 | $2.0M | 12/12/2024 | View on chart |
| CADL | ▼ Sell | Other | 200,000 | $2.0M | 12/12/2024 | View on chart |
| CADL | ▼ Sell | Other | 200,000 | $1.7M | 12/11/2024 | View on chart |
| CADL | ▼ Sell | Other | 200,000 | $1.7M | 12/11/2024 | View on chart |
| CADL | ▼ Sell | Other | 20,000 | $105K | 12/6/2024 | View on chart |
| CADL | ▼ Sell | Other | 20,000 | $96K | 12/5/2024 | View on chart |
| CADL | ▼ Sell | Other | 20,000 | $89K | 12/4/2024 | View on chart |
| CADL | ▼ Sell | Other | 20,000 | $99K | 11/25/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $37K | 11/8/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $37K | 11/8/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $39K | 11/7/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $39K | 11/7/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 11/6/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 11/6/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 11/1/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 11/1/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 10/31/2024 | View on chart |
| CADL | ▼ Sell | Other | 7,500 | $40K | 10/31/2024 | View on chart |
| CADL | ▼ Sell | Other | 6,000 | $32K | 10/30/2024 | View on chart |
| CADL | ▼ Sell | Other | 6,000 | $32K | 10/30/2024 | View on chart |
| CADL | ▼ Sell | Other | 11,711 | $65K | 10/28/2024 | View on chart |
| CADL | ▼ Sell | Other | 1,597 | $9K | 10/25/2024 | View on chart |
| CADL | ▼ Sell | Other | 16,427 | $91K | 10/24/2024 | View on chart |
| CADL | ▼ Sell | Other | 1,194 | $7K | 10/24/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 10,412 | $63K | 10/15/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 15,000 | $90K | 10/14/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 15,000 | $91K | 10/11/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 1,800 | $12K | 10/3/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 26,988 | $187K | 10/2/2024 | View on chart |
| CADL | ▼ Sell | Open Market | 6,214 | $44K | 10/1/2024 | View on chart |
| CADL | ▲ Buy | Option Exercise | 135,183 | $197K | 5/6/2022 | View on chart |
| CADL | ▼ Sell | Tax Withholding | 54,074 | $197K | 5/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Candel Therapeutics Issues Inducement Grants to New Employees
Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.
Candel Therapeutics Issues Inducement Grants to New Employees. Candel Therapeutics disclosed standard inducement grants awarded to newly hired employees. Under Nasdaq rules, such grants require public disclosure when given as incentives to attract talent. This is routine corporate governance news with no material impact on the company's operations or financial position. The grants align with standard market practices for biotechnology firms building their teams.